These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 8786083

  • 1. No mutations found by RET mutation scanning in sporadic and hereditary neuroblastoma.
    Hofstra RM, Cheng NC, Hansen C, Stulp RP, Stelwagen T, Clausen N, Tommerup N, Caron H, Westerveld A, Versteeg R, Buys CH.
    Hum Genet; 1996 Mar; 97(3):362-4. PubMed ID: 8786083
    [Abstract] [Full Text] [Related]

  • 2. Absence of MEN2A- or 2B-type RET mutations in primary neuroblastoma tumour tissue.
    Peaston AE, Camacho ML, Norris MD, Haber M, Marsh DJ, Robinson BG, Hyland VJ, Marshall GM.
    Mol Cell Probes; 1998 Aug; 12(4):239-42. PubMed ID: 9727201
    [Abstract] [Full Text] [Related]

  • 3. Frequency of RET mutations in long- and short-segment Hirschsprung disease.
    Seri M, Yin L, Barone V, Bolino A, Celli I, Bocciardi R, Pasini B, Ceccherini I, Lerone M, Kristoffersson U, Larsson LT, Casasa JM, Cass DT, Abramowicz MJ, Vanderwinden JM, Kravcenkiene I, Baric I, Silengo M, Martucciello G, Romeo G.
    Hum Mutat; 1997 Aug; 9(3):243-9. PubMed ID: 9090527
    [Abstract] [Full Text] [Related]

  • 4. Low frequency of RET mutations in Hirschsprung disease in Sweden.
    Svensson PJ, Molander ML, Eng C, Anvret M, Nordenskjöld A.
    Clin Genet; 1998 Jul; 54(1):39-44. PubMed ID: 9727738
    [Abstract] [Full Text] [Related]

  • 5. Heterogeneity and low detection rate of RET mutations in Hirschsprung disease.
    Yin L, Barone V, Seri M, Bolino A, Bocciardi R, Ceccherini I, Pasini B, Tocco T, Lerone M, Cywes S.
    Eur J Hum Genet; 1994 Jul; 2(4):272-80. PubMed ID: 7704557
    [Abstract] [Full Text] [Related]

  • 6. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P.
    Verh Dtsch Ges Pathol; 1995 Jul; 79():L-LV. PubMed ID: 8600671
    [Abstract] [Full Text] [Related]

  • 7. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease.
    Attié T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, Boutrand L, Beldjord C, Nihoul-Fékété C, Munnich A.
    Hum Mol Genet; 1995 Aug; 4(8):1381-6. PubMed ID: 7581377
    [Abstract] [Full Text] [Related]

  • 8. Specific expression of the ret proto-oncogene in human neuroblastoma cell lines.
    Ikeda I, Ishizaka Y, Tahira T, Suzuki T, Onda M, Sugimura T, Nagao M.
    Oncogene; 1990 Sep; 5(9):1291-6. PubMed ID: 2216455
    [Abstract] [Full Text] [Related]

  • 9. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.
    Woodward ER, Eng C, McMahon R, Voutilainen R, Affara NA, Ponder BA, Maher ER.
    Hum Mol Genet; 1997 Jul; 6(7):1051-6. PubMed ID: 9215674
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M, Jackson CE, Feldman GL.
    Hum Mutat; 1996 Jul; 8(1):64-70. PubMed ID: 8807338
    [Abstract] [Full Text] [Related]

  • 12. RET proto-oncogene point mutations in sporadic neuroendocrine tumors.
    Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WK, Heitz PU.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2041-6. PubMed ID: 8964826
    [Abstract] [Full Text] [Related]

  • 13. RET and GDNF gene scanning in Hirschsprung patients using two dual denaturing gel systems.
    Hofstra RM, Wu Y, Stulp RP, Elfferich P, Osinga J, Maas SM, Siderius L, Brooks AS, vd Ende JJ, Heydendael VM, Severijnen RS, Bax KM, Meijers C, Buys CH.
    Hum Mutat; 2000 Jun; 15(5):418-29. PubMed ID: 10790203
    [Abstract] [Full Text] [Related]

  • 14. A 5'-CG-3'-rich region in the promoter of the transcriptionally frequently silenced RET protooncogene lacks methylated cytidine residues.
    Munnes M, Patrone G, Schmitz B, Romeo G, Doerfler W.
    Oncogene; 1998 Nov 19; 17(20):2573-83. PubMed ID: 9840920
    [Abstract] [Full Text] [Related]

  • 15. Induction of RET proto-oncogene expression in neuroblastoma cells precedes neuronal differentiation and is not mediated by protein synthesis.
    Bunone G, Borrello MG, Picetti R, Bongarzone I, Peverali FA, de Franciscis V, Della Valle G, Pierotti MA.
    Exp Cell Res; 1995 Mar 19; 217(1):92-9. PubMed ID: 7867726
    [Abstract] [Full Text] [Related]

  • 16. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
    Eng C, Mulligan LM.
    Hum Mutat; 1997 Mar 19; 9(2):97-109. PubMed ID: 9067749
    [Abstract] [Full Text] [Related]

  • 17. Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells.
    D'Alessio A, De Vita G, Calì G, Nitsch L, Fusco A, Vecchio G, Santelli G, Santoro M, de Franciscis V.
    Cell Growth Differ; 1995 Nov 19; 6(11):1387-94. PubMed ID: 8562477
    [Abstract] [Full Text] [Related]

  • 18. Alterations of RET oncogene in human adrenal tumors.
    Lin SR, Yang YC, Tsai JH, Hsu CH.
    Jpn J Cancer Res; 1998 Jun 19; 89(6):634-40. PubMed ID: 9703361
    [Abstract] [Full Text] [Related]

  • 19. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease.
    Angrist M, Bolk S, Thiel B, Puffenberger EG, Hofstra RM, Buys CH, Cass DT, Chakravarti A.
    Hum Mol Genet; 1995 May 19; 4(5):821-30. PubMed ID: 7633441
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.